| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE38506 | MSD SUB MERCK | Potent inducers of terminal differentiation and methods of use thereof |
Jul, 2015
(8 years ago) | |
| US7456219 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7652069 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(1 year, 1 month ago) | |
| US8067472 | MSD SUB MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(1 year, 1 month ago) | |
| US8101663 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(1 year, 1 month ago) | |
| US7732490 | MSD SUB MERCK | Methods of treating cancer |
Mar, 2023
(1 year, 1 month ago) | |
| US7851509 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(a month ago) | |
| US7399787 | MSD SUB MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(9 months from now) | |
| US8093295 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(2 years from now) | |
| US8450372 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(3 years from now) | |
Zolinza is owned by Msd Sub Merck.
Zolinza contains Vorinostat.
Zolinza has a total of 10 drug patents out of which 6 drug patents have expired.
Expired drug patents of Zolinza are:
- US7652069
- US8067472
- US8101663
- US7732490
- US7851509
- USRE38506
Zolinza was authorised for market use on 06 October, 2006.
Zolinza is available in capsule;oral dosage forms.
Zolinza can be used as treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl).
Drug patent challenges can be filed against Zolinza from 06 October, 2010.
The generics of Zolinza are possible to be released after 18 March, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE;ORAL
ZOLINZA family patents
